» Articles » PMID: 18186055

Cannabinoid Receptor 1 Gene (CNR1) and Susceptibility to a Quantitative Phenotype for Hebephrenic Schizophrenia

Abstract

Functional alterations of components of the endogenous cannabinoid system, in particular of the cannabinoid receptor 1 protein (CB1), are hypothetical contributors to many of the symptoms seen in schizophrenia. Variants within the cannabinoid receptor 1 gene (CNR1) have been shown to be directly associated with the hebephrenic form of schizophrenia in a Japanese population. This finding, however, has yet to be replicated. In the present study we sought to study the same (AAT)n-repeat microsatellite of the CNR1 gene which showed association to hebephrenic schizophrenia in Japan, and to investigate whether this microsatellite showed association to a hebephrenic type of schizophrenia in a family-based association study in a population of the Central Valley of Costa Rica. The Lifetime Dimensions of Psychosis Scale and a best estimate consensus process were utilized to identify subjects with schizophrenia who had an elevated lifetime dimensional score for negative and disorganized symptoms, which we used as a proxy for "hebephrenia." Using the Family Based Association Test we found association of these hebephrenic subjects and the (AAT)n-repeat marker of the CNR1 (multi-allelic P = 0.0368). Our hypothesis that an association with the (AAT)n-repeat marker of CNR1 would not be found with the more general type of schizophrenia was also confirmed. Schizophrenic subjects with prominent lifetime scores for disorganization and negative symptoms (dimension for hebephrenia) are associated with the CNR1 gene and present a type of symptomatology that resembles chronic cannabinoid-induced psychosis. The current finding points to the possibility of different genetic and pathophysiologic mechanisms underlying different types of schizophrenia.

Citing Articles

Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.

Kumar U Int J Mol Sci. 2025; 26(1.

PMID: 39796008 PMC: 11720483. DOI: 10.3390/ijms26010152.


Clinical and cognitive outcomes in first-episode psychosis: focus on the interplay between cannabis use and genetic variability in endocannabinoid receptors.

Oscoz-Irurozqui M, Guardiola-Ripoll M, Almodovar-Paya C, Guerrero-Pedraza A, Hostalet N, Carrion M Front Psychol. 2024; 15:1414098.

PMID: 39193030 PMC: 11348434. DOI: 10.3389/fpsyg.2024.1414098.


Cannabis Pharmacogenomics: A Path to Personalized Medicine.

Babayeva M, Loewy Z Curr Issues Mol Biol. 2023; 45(4):3479-3514.

PMID: 37185752 PMC: 10137111. DOI: 10.3390/cimb45040228.


Dopamine Related Genes Differentially Affect Declarative Long-Term Memory in Healthy Humans.

Leukel C, Schumann D, Kalisch R, Sommer T, Bunzeck N Front Behav Neurosci. 2020; 14:539725.

PMID: 33328916 PMC: 7673390. DOI: 10.3389/fnbeh.2020.539725.


Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients.

Stertz L, Di Re J, Pei G, Fries G, Mendez E, Li S Neuropsychopharmacology. 2020; 46(3):673-682.

PMID: 33288841 PMC: 8027596. DOI: 10.1038/s41386-020-00924-0.